Abstract: An embodiment of a memory apparatus may include a logger to log memory access data in persistent storage media, a log indexer communicatively coupled to the logger to index the memory access log data in an index table in a system memory, and a key compressor communicatively coupled to the log indexer to compress an index key for the index table. Other embodiments are disclosed and claimed.

Abstract: Peptides useful as inflammasome inhibitors are disclosed and can comprise an H2 helix of a pyrin domain, wherein at least two non-consecutive amino acids of the H2 helix are covalently linked. Methods of treating a subject with a disease comprising administering to the subject the disclosed peptides are also disclosed. Further, disclosed herein are methods of inhibiting binding between a first polypeptide comprising a pyrin domain and a second polypeptide comprising a pyrin domain, the method comprising contacting either the first polypeptide or the second polypeptide with the disclosed peptides.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: In one aspect, the invention relates to 4-substituted benzoylpiperazine-1-substituted carbonyls, derivatives thereof, and related compounds; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with ?-catenin/BCL9 protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over D-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed are inhibitors for the ?-catenin/T-cell factor interaction. The inhibitors are selective for ?-catenin/T-cell factor over ?-catenin/cadherin and ?-catenin/APC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: An embodiment of a memory apparatus may include a logger to log memory access data in persistent storage media, a log indexer communicatively coupled to the logger to index the memory access log data in an index table in a system memory, and a key compressor communicatively coupled to the log indexer to compress an index key for the index table. Other embodiments are disclosed and claimed.

Abstract: Embodiments of the present disclosure provide devices, techniques, and configurations for network interface controllers (NICs) that log write packets received from a network in non-volatile random access memory (NVRAM). In one embodiment, a NIC includes a network interface to couple a host of the NIC to a network, a NVRAM, and a controller coupled with the network interface and the NVRAM, where the controller is to log write packets received at the network interface from the network in the NVRAM. Other embodiments may be described and/or claimed.

Abstract: Provided is an apparatus directing to a speculative read mechanism for a distributed storage system. The apparatus includes a remote direct memory access (RDMA) network interface card (RNIC) (100) for a server (250), wherein the RNIC (100) includes an onboard memory (105), a trigger control (120) and a port for connection of the RNIC (100) to a client (200). The onboard memory (105) is operable to provide a buffer (110) for storage of data from a distributed storage system for a read request from the client (200). The trigger control (120) includes a programmable trigger condition. The RNIC (100) is operable to support a speculative read of data in response to a read request snoop of a write of data to the onboard memory (105), and upon detecting the trigger condition, to provide the data in the buffer to the client (200).

Abstract: In one aspect, the invention relates to substituted 5H-[1,2,5]oxadiazolo [3?,4?:5,6]pyrazino[2,3-b]indole analogs, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and A methods of treating disorders, e.g., various tumors and cancers, associated with a ?-catenin/T-cell factor interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, the invention relates to substituted 5H-[1,2,5]oxadiazolo [3?,4?:5,6]pyrazino[2,3-b]indole analogues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and A methods of treating disorders, e.g., various tumors and cancers, associated with a ?-catenin/T-cell factor interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, the invention relates to substituted N-([1,1?-biphenyl]-3-yl)-[1,1?-biphenyl]-3-carboxamide analogues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with ?-Catenin/BCL9 protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, the invention relates to substituted 1H-benzo[d][1,2,3]triazol-1-ol analgoues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g. various tumors and cancers, associated with ?-catenin/Tcf protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, the invention relates to substituted 1H-benzo[d][1,2,3]triazol-1-ol analgoues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g. various tumors and cancers, associated with ?-catenin/Tcf protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, the invention relates to substituted 1H-benzo[d][1,2,3]triazol-1-ol analgoues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g. various tumors and cancers, associated with ?-catenin/Tcf protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.

Abstract: In one aspect, the invention relates to substituted 1H-benzo[d][1,2,3]triazol-1-ol analgoues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g. various tumors and cancers, associated with ?-catenin/Tcf protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.

Abstract: Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.

Abstract: Compounds and related methods for selective inhibition of neuronal nitric oxide synthase over inducible and endothelial isoforms, such compounds as can provide reduced cationic character and enhanced bioavailability.